6DMAP inhibition of early cell cycle events and induction of mitotic abnormalities

Marcella Simili, Paola Pellerano, Simona Pigullo, Gaia Tavosanis, Laura Ottaggio, Louis De Saint-Georges, Stefania Bonatti

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

N-6 dimethylaminopurine (6DMAP) has been shown to induce aberrant mitosis in different cell types including Chinese hamster fibroblasts (CHEF/18). The mechanism of action and the cellular targets, however, are still not clear. We showed previously that in CHEF/18 cells this compound inhibits DNA synthesis with a kinetic of inhibition suggestive of an effect on early events of the cell cycle. In this paper we investigated which cellular targets were affected by 6DMAP and found that: (i) the compound inhibits phosphorylation of ribosomal protein S6 and activation of the 70 KDa S6 kinase (p70(S6k)) known to be activated by epidermal growth factor (EGF) in keeping with the notion that it is a protein kinase inhibitor; however the inhibition in vivo appears to be specific as MAP kinase phosphorylation is not inhibited; (ii) 6DMAP drastically affects cytoskeletal components leading to a rapid morphological change in most cells. These data, together with the findings that the dose range and the treatment time effective in inducing the micronuclei containing chromosomes were the same as for DNA synthesis inhibition, suggest that a disturbance in G1 of signal transduction pathways may contribute to abnormal mitosis.

Original languageEnglish
Pages (from-to)313-319
Number of pages7
JournalMutagenesis
Volume12
Issue number5
DOIs
Publication statusPublished - 1997

Fingerprint

Cell Cycle
Phosphorylation
Cells
Mitosis
Ribosomal Protein S6
70-kDa Ribosomal Protein S6 Kinases
Signal transduction
DNA
Fibroblasts
Protein Kinase Inhibitors
Chromosomes
Cricetulus
Epidermal Growth Factor
Signal Transduction
Phosphotransferases
Chemical activation
Kinetics
N(6),N(6)-dimethyladenine
compound 18

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)
  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

Simili, M., Pellerano, P., Pigullo, S., Tavosanis, G., Ottaggio, L., De Saint-Georges, L., & Bonatti, S. (1997). 6DMAP inhibition of early cell cycle events and induction of mitotic abnormalities. Mutagenesis, 12(5), 313-319. https://doi.org/10.1093/mutage/12.5.313

6DMAP inhibition of early cell cycle events and induction of mitotic abnormalities. / Simili, Marcella; Pellerano, Paola; Pigullo, Simona; Tavosanis, Gaia; Ottaggio, Laura; De Saint-Georges, Louis; Bonatti, Stefania.

In: Mutagenesis, Vol. 12, No. 5, 1997, p. 313-319.

Research output: Contribution to journalArticle

Simili, M, Pellerano, P, Pigullo, S, Tavosanis, G, Ottaggio, L, De Saint-Georges, L & Bonatti, S 1997, '6DMAP inhibition of early cell cycle events and induction of mitotic abnormalities', Mutagenesis, vol. 12, no. 5, pp. 313-319. https://doi.org/10.1093/mutage/12.5.313
Simili M, Pellerano P, Pigullo S, Tavosanis G, Ottaggio L, De Saint-Georges L et al. 6DMAP inhibition of early cell cycle events and induction of mitotic abnormalities. Mutagenesis. 1997;12(5):313-319. https://doi.org/10.1093/mutage/12.5.313
Simili, Marcella ; Pellerano, Paola ; Pigullo, Simona ; Tavosanis, Gaia ; Ottaggio, Laura ; De Saint-Georges, Louis ; Bonatti, Stefania. / 6DMAP inhibition of early cell cycle events and induction of mitotic abnormalities. In: Mutagenesis. 1997 ; Vol. 12, No. 5. pp. 313-319.
@article{10dab7644ef1434c8fc9bd26b3a027d0,
title = "6DMAP inhibition of early cell cycle events and induction of mitotic abnormalities",
abstract = "N-6 dimethylaminopurine (6DMAP) has been shown to induce aberrant mitosis in different cell types including Chinese hamster fibroblasts (CHEF/18). The mechanism of action and the cellular targets, however, are still not clear. We showed previously that in CHEF/18 cells this compound inhibits DNA synthesis with a kinetic of inhibition suggestive of an effect on early events of the cell cycle. In this paper we investigated which cellular targets were affected by 6DMAP and found that: (i) the compound inhibits phosphorylation of ribosomal protein S6 and activation of the 70 KDa S6 kinase (p70(S6k)) known to be activated by epidermal growth factor (EGF) in keeping with the notion that it is a protein kinase inhibitor; however the inhibition in vivo appears to be specific as MAP kinase phosphorylation is not inhibited; (ii) 6DMAP drastically affects cytoskeletal components leading to a rapid morphological change in most cells. These data, together with the findings that the dose range and the treatment time effective in inducing the micronuclei containing chromosomes were the same as for DNA synthesis inhibition, suggest that a disturbance in G1 of signal transduction pathways may contribute to abnormal mitosis.",
author = "Marcella Simili and Paola Pellerano and Simona Pigullo and Gaia Tavosanis and Laura Ottaggio and {De Saint-Georges}, Louis and Stefania Bonatti",
year = "1997",
doi = "10.1093/mutage/12.5.313",
language = "English",
volume = "12",
pages = "313--319",
journal = "Mutagenesis",
issn = "0267-8357",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - 6DMAP inhibition of early cell cycle events and induction of mitotic abnormalities

AU - Simili, Marcella

AU - Pellerano, Paola

AU - Pigullo, Simona

AU - Tavosanis, Gaia

AU - Ottaggio, Laura

AU - De Saint-Georges, Louis

AU - Bonatti, Stefania

PY - 1997

Y1 - 1997

N2 - N-6 dimethylaminopurine (6DMAP) has been shown to induce aberrant mitosis in different cell types including Chinese hamster fibroblasts (CHEF/18). The mechanism of action and the cellular targets, however, are still not clear. We showed previously that in CHEF/18 cells this compound inhibits DNA synthesis with a kinetic of inhibition suggestive of an effect on early events of the cell cycle. In this paper we investigated which cellular targets were affected by 6DMAP and found that: (i) the compound inhibits phosphorylation of ribosomal protein S6 and activation of the 70 KDa S6 kinase (p70(S6k)) known to be activated by epidermal growth factor (EGF) in keeping with the notion that it is a protein kinase inhibitor; however the inhibition in vivo appears to be specific as MAP kinase phosphorylation is not inhibited; (ii) 6DMAP drastically affects cytoskeletal components leading to a rapid morphological change in most cells. These data, together with the findings that the dose range and the treatment time effective in inducing the micronuclei containing chromosomes were the same as for DNA synthesis inhibition, suggest that a disturbance in G1 of signal transduction pathways may contribute to abnormal mitosis.

AB - N-6 dimethylaminopurine (6DMAP) has been shown to induce aberrant mitosis in different cell types including Chinese hamster fibroblasts (CHEF/18). The mechanism of action and the cellular targets, however, are still not clear. We showed previously that in CHEF/18 cells this compound inhibits DNA synthesis with a kinetic of inhibition suggestive of an effect on early events of the cell cycle. In this paper we investigated which cellular targets were affected by 6DMAP and found that: (i) the compound inhibits phosphorylation of ribosomal protein S6 and activation of the 70 KDa S6 kinase (p70(S6k)) known to be activated by epidermal growth factor (EGF) in keeping with the notion that it is a protein kinase inhibitor; however the inhibition in vivo appears to be specific as MAP kinase phosphorylation is not inhibited; (ii) 6DMAP drastically affects cytoskeletal components leading to a rapid morphological change in most cells. These data, together with the findings that the dose range and the treatment time effective in inducing the micronuclei containing chromosomes were the same as for DNA synthesis inhibition, suggest that a disturbance in G1 of signal transduction pathways may contribute to abnormal mitosis.

UR - http://www.scopus.com/inward/record.url?scp=0030858115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030858115&partnerID=8YFLogxK

U2 - 10.1093/mutage/12.5.313

DO - 10.1093/mutage/12.5.313

M3 - Article

C2 - 9379908

AN - SCOPUS:0030858115

VL - 12

SP - 313

EP - 319

JO - Mutagenesis

JF - Mutagenesis

SN - 0267-8357

IS - 5

ER -